Hypovitaminosis D is associated with depression and anxiety in schizophrenia: Results from the national FACE-SZ cohort.

G Fond, O Godin, F Schürhoff, F Berna, E Bulzacka, M Andrianarisoa, L Brunel, B Aouizerate, D Capdevielle, I Chereau, N Coulon, T D'Amato, C Dubertret, J Dubreucq, C Faget, C Lançon, S Leignier, J Mallet, D Misdrahi, C Passerieux, R Rey, A Schandrin, M Urbach, P Vidailhet, M Leboyer, L Boyer, PM Llorca
Psychiatry Research. 2018-12-01; 270: 104-110
DOI: 10.1016/j.psychres.2018.09.024

PubMed
Lire sur PubMed



1. Psychiatry Res. 2018 Dec;270:104-110. doi: 10.1016/j.psychres.2018.09.024.
Epub 2018 Sep 13.

Hypovitaminosis D is associated with depression and anxiety in schizophrenia:
Results from the national FACE-SZ cohort.

Fond G(1), Godin O(2), Schürhoff F(3), Berna F(4), Bulzacka E(3), Andrianarisoa
M(3), Brunel L(3), Aouizerate B(5), Capdevielle D(6), Chereau I(7), Coulon N(3),
D’Amato T(8), Dubertret C(9), Dubreucq J(10), Faget C(11), Lançon C(11),
Leignier S(10), Mallet J(9), Misdrahi D(12), Passerieux C(13), Rey R(8),
Schandrin A(6), Urbach M(13), Vidailhet P(14), Leboyer M(3), Boyer L(11), Llorca
PM(7); FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia)
group.

Author information:
(1)Fondation FondaMental, Créteil, France; Aix-Marseille Univ, Faculté de
Médecine – Secteur Timone, Assistance Publique des Hopitaux de Marseille
(AP-HM), EA 3279: CEReSS -Centre d’Etude et de Recherche sur les Services de
Santé et la Qualité de vie, 27 Boulevard Jean Moulin, Marseille 13005, France.
Electronic address: .
(2)Fondation FondaMental, Créteil, France; Sorbonne Universités, UPMC Univ Paris
06, UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique,
INSERM, UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique,
Paris F-75013, France.
(3)Fondation FondaMental, Créteil, France; INSERM U955, équipe de psychiatrie
translationnelle, Université Paris-Est Créteil, DHU Pe-PSY, Pôle de Psychiatrie
des Hôpitaux Universitaires H Mondor, Créteil, France.
(4)Fondation FondaMental, Créteil, France; Hôpitaux Universitaires de
Strasbourg, Université de Strasbourg, INSERM U1114, Fédération de Médecine
Translationnelle de Strasbourg, Strasbourg, France.
(5)Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens,
Université de Bordeaux, Bordeaux F-33076, France; INRA, NutriNeuro, University
of Bordeaux, U1286, Bordeaux F-33076, France.
(6)Fondation FondaMental, Créteil, France; Service Universitaire de Psychiatrie
Adulte, Hôpital la Colombière, CHRU Montpellier, Université Montpellier 1,
Inserm 1061, Montpellier, France.
(7)Fondation FondaMental, Créteil, France; CMP B, CHU, EA 7280 Faculté de
Médecine, Université d’Auvergne, BP 69 63003, Clermont-Ferrand Cedex 1, France.
(8)Fondation FondaMental, Créteil, France; INSERM U1028, CNRS UMR5292, Centre de
Recherche en Neurosciences de Lyon, Université Claude Bernard Lyon 1, Equipe
PSYR2, Centre Hospitalier Le Vinatier, Pole Est, 95 bd Pinel, BP 30039, Bron
Cedex 69678, France.
(9)Fondation FondaMental, Créteil, France; AP-HP, Department of Psychiatry,
Louis Mourier Hospital, Colombes, Inserm U894, Université Paris Diderot,
Sorbonne Paris Cité, Faculté de médecine, France.
(10)Fondation FondaMental, Créteil, France; Centre Référent de Réhabilitation
Psychosociale, CH Alpes Isère, Grenoble, France.
(11)Fondation FondaMental, Créteil, France; Aix-Marseille Univ, Faculté de
Médecine – Secteur Timone, Assistance Publique des Hopitaux de Marseille
(AP-HM), EA 3279: CEReSS -Centre d’Etude et de Recherche sur les Services de
Santé et la Qualité de vie, 27 Boulevard Jean Moulin, Marseille 13005, France.
(12)Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens,
Université de Bordeaux, Bordeaux F-33076, France; CNRS UMR 5287-INCIA.
(13)Fondation FondaMental, Créteil, France; Centre Hospitalier de Versailles,
Service de psychiatrie et d’addictologie adulte, Le Chesnay, EA 4047 HANDIReSP,
UFR des Sciences de la Santé Simone Veil, Université Versailles
Saint-Quentin-en-Yvelines, Versailles, France.
(14)Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM
U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg,
France.

OBJECTIVE: Hypovitaminosis D has been associated with respectively major
depressive disorder, schizophrenia (SZ) and cognitive disorders in the general
population, and with positive and negative symptoms and metabolic syndrome in
schizophrenia. The objectives were (i) to determine the prevalence of
hypovitaminosis D and associated factors (with a focus on depression and
cognition) in a national non-selected multicentric sample of community-dwelling
SZ subjects (ii) to determine the rate of SZ patients being administered vitamin
D supplementation and associated factors.
METHODS: A comprehensive 2 daylong clinical and neuropsychological battery was
administered in 140 SZ subjects included between 2015 and 2017 in the national
FondaMental Expert Center (FACE-SZ) Cohort. Hypovitaminosis D was defined by
blood vitamin D level  0.05), however, a trend toward significance has been found for
metabolic syndrome (p = 0.06). Vitamin D supplementation has been administered
during the previous 12 months in only 8.5% of the subjects but was associated
with lower depressive symptoms (aOR = 0.67 [0.46-0.98], p = 0.04) and lower rate
of current anxiety disorder (aOR = 0.06 [0.01-0.66], p = 0.02) compared to
patients with hypovitaminosis D.
CONCLUSION: Hypovitaminosis D is frequent and associated with depressive
symptoms and anxiety disorders in schizophrenia. Vitamin D supplementation is
associated with lower depressive and anxiety symptoms, however patients with
hypovitaminosis D remain insufficiently treated.

Copyright © 2018. Published by Elsevier B.V.

DOI: 10.1016/j.psychres.2018.09.024
PMID: 30245372 [Indexed for MEDLINE]

Auteurs Bordeaux Neurocampus